Zevra Therapeutics, Inc. — Cash Flow Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Capital Allocation Waterfall
Buybacks vs Stock-Based Comp
Net Debt Issuance
Cash Flow
Cash Flow by Activity
Operating Cash Flow
$6M
Free Cash Flow
$6M
Investing Cash Flow
$227K
Financing Cash Flow↑+219.8% +$2M
$3M
Capex
$554K
Acquisitions
$0
Stock Buybacks
$0
Stock-Based Comp↑+6.6% +$266K
$4M
Debt Issued
$0
Debt Repaid
$0
D&A↓-78.0% -$1M
$362K
SBC Allocated Expense↑+6.6% +$266K
$4M